Point72 DIFC Ltd Takes Position in Candel Therapeutics, Inc. (NASDAQ:CADL)

Point72 DIFC Ltd purchased a new position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,927 shares of the company’s stock, valued at approximately $31,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers acquired a new stake in Candel Therapeutics in the 2nd quarter worth about $143,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Candel Therapeutics in the second quarter worth approximately $162,000. Finally, Bank of New York Mellon Corp acquired a new position in Candel Therapeutics in the 2nd quarter valued at $338,000. 13.93% of the stock is owned by hedge funds and other institutional investors.

Candel Therapeutics Trading Down 1.5 %

Shares of CADL stock opened at $6.71 on Friday. Candel Therapeutics, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $14.30. The firm has a market capitalization of $199.66 million, a P/E ratio of -5.24 and a beta of -0.95. The stock’s fifty day moving average is $6.24 and its two-hundred day moving average is $6.48. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.62 and a current ratio of 1.62.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. Research analysts expect that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Transactions at Candel Therapeutics

In related news, CEO Paul Peter Tak sold 20,293 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $5.97, for a total value of $121,149.21. Following the completion of the sale, the chief executive officer now owns 353,263 shares of the company’s stock, valued at $2,108,980.11. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Candel Therapeutics news, CEO Paul Peter Tak sold 20,293 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $5.97, for a total value of $121,149.21. Following the completion of the sale, the chief executive officer now directly owns 353,263 shares of the company’s stock, valued at approximately $2,108,980.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Charles Schoch sold 8,897 shares of the business’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $5.97, for a total transaction of $53,115.09. Following the transaction, the insider now directly owns 72,404 shares in the company, valued at approximately $432,251.88. The disclosure for this sale can be found here. Insiders have sold a total of 91,583 shares of company stock worth $571,966 in the last ninety days. Insiders own 41.60% of the company’s stock.

Candel Therapeutics Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.